TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07645287: A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Vi

Sponsor: Gilead Sciences · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 175 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,323,000

Rescue Site Savings

+$882,000

Unlock Full NCT07645287 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07645287 Rescue Dossier →